about
Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort studyHistological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study.Mycotic aneurysm of the aorta as a complication of Bacillus Calmette-Guérin instillation.ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors.ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II - Management of Various Cardiovascular Complications.Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort StudyTowards standardized reporting in studies of encapsulating peritoneal sclerosis.Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival.Longitudinal study of small solute transport and peritoneal protein clearance in peritoneal dialysis patients.Determinants of peritoneal membrane function over time.miR-21 Promotes Fibrogenesis in Peritoneal Dialysis.Ethnicity, age and incidence rates for renal replacement therapy (RRT) in Birmingham, UK: 1990-2004.Long-term changes in solute and water transport.A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent.The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis.Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study.The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made.Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis - Position Paper for ISPD: 2017 Update.Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis.Are Peritoneal Dialysis Center Characteristics a Modifiable Risk Factor to Improve Peritoneal Dialysis Outcomes?Biocompatible Solutions and Long-Term Changes in Peritoneal Solute TransportProof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosisPeritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis PatientsUse of tunnelled haemodialysis catheters at the start of haemodialysis--success rates and definition of infectionCryofiltration in the treatment of cryoglobulinemia and HLA antibody-incompatible transplantationTransition between home dialysis modalities: another piece in the jigsaw of the integrated care pathwayUnited Kingdom Catheter Study - Protocol SynopsisUK Renal Registry 19th Annual Report: Chapter 13 Home Therapies in 2015: National and Centre-specific AnalysesTransition Between Different Renal Replacement Modalities: Gaps in Knowledge and Care-The Integrated Research InitiativeAttitudes toward Peritoneal Dialysis among Peritoneal Dialysis and Hemodialysis Medical Directors: Are We Preaching to the Right Choir?Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of deathHow unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies
P50
Q34071743-6F741B69-395A-45E8-8756-CBBC786C8883Q34110645-4EFF7383-7A90-4F5A-86C7-A56F62BE0F24Q34192991-347C24A9-5EA0-4CBA-8023-B0F635903355Q35904398-850A2497-A313-44C2-9542-872660E05A7FQ35904403-C6A89E6F-AE32-4F7C-9C77-49271C72D641Q36036289-B2C4834B-1BF9-4741-8EE2-A1CF7DCF4C43Q37232268-E70A0000-530A-451C-B12D-936FD061A91EQ37340225-CCB83280-BE68-4A54-AE48-0B247C1F08AEQ37553046-A8B8575F-805F-4ED4-8199-FE5B6007EF9BQ37857972-33010560-9455-4545-B95D-B60F0835660CQ38791086-3B1C40B3-2239-4FB9-BDF6-DCF90962454AQ39851956-F66FB0C8-5702-481B-AFF1-516ACA5386AFQ39973840-12C2B674-1530-4027-9704-2AC5BA948BC2Q40148780-F9768F8A-7F86-45CD-8A18-F62253232AE9Q40365419-F2BACF86-8522-48A3-91DA-EABE231DF952Q40779756-A39A2045-10D3-4EF3-9A82-BA7C732F2C68Q43008381-4E5159B3-91E2-4D41-A0F6-B58B5A9E9E67Q49082243-7D4B5E90-8F19-4C57-94CA-289D68999C58Q55256921-A8A6FCCA-C573-4ABD-AF39-9979541F6E13Q55482456-3FE961CD-39BB-46EA-82BA-1E9E631A55DBQ57293923-5DE39A96-61EC-45B8-9E15-35424A586C9EQ57797449-BCCC0C03-CB05-4777-93E1-D6D0DC7AC09AQ64226729-EBBE2B04-2547-4163-8E44-447AC327225DQ80050507-9A5A9CE3-2A3B-4CB2-A518-A7CA983791A4Q83251529-A0FD65FC-71D5-465E-8431-B36E89DFA717Q85640323-71B291CB-58C1-43AE-B710-8A0FDFF3734CQ88124220-CEFCF4C6-94DA-4A9B-964B-0BA1A60CFAE0Q89031616-2086FFB7-9911-42AA-B5E5-75F1A8985C19Q91258432-11CB3FE9-06EF-4AEC-A0DF-6A45EB2537D3Q91663881-7FB9B314-C660-4AB3-9B10-00C6DEEE2F4BQ92026702-D0B181F4-2D2A-446C-BB52-E2748384BB17Q92317855-940F48BB-B01D-444B-9E54-B87C1D928FE5
P50
description
researcher ORCID ID = 0000-0002-6285-5368
@en
wetenschapper
@nl
name
Mark Lambie
@ast
Mark Lambie
@en
Mark Lambie
@es
Mark Lambie
@nl
type
label
Mark Lambie
@ast
Mark Lambie
@en
Mark Lambie
@es
Mark Lambie
@nl
prefLabel
Mark Lambie
@ast
Mark Lambie
@en
Mark Lambie
@es
Mark Lambie
@nl
P106
P21
P31
P496
0000-0002-6285-5368